ONCTERNAL THERAPEUTICS is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medial need. They are committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types. As of the end of 2018, ONCTERNAL drug candidates were in Phase 1 clinical trials against chronic lymphocytic leukemia (CLL), advanced breast cancer, and Ewing sarcoma.

www.oncternal.com